Clinical Trial Update: European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients [Phase 2]

View source ↗

Summary

The Phase 2 European trial of HF0220 in mild-to-moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• HF0220

Snippet

Sponsor: Hunter-Fleming Ltd | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED